Detailed Narrative
Q1 Financial Outperformance and Raised Guidance
Hinge Health significantly exceeded its Q1 expectations, reporting $182 million in revenue, a 47% year-over-year increase, and $46 million in operating income, well above the $30 million to $32 million guidance. This strong performance, driven by better-than-expected billings from higher yields and eligible lives, led management to raise its full-year 2026 revenue guidance to $798 million-$804 million and operating income guidance to $205 million-$215 million. The upward revision is attributed equally to yield improvements and growth in eligible lives, with AI-driven efficiencies contributing to margin expansion.
Launch of Migraine Care Program and Platform Expansion
The company launched its Migraine Care Program, marking its first expansion beyond musculoskeletal (MSK) pain. This program leverages Hinge Health's existing platform and the FDA-cleared Enso neuromodulation device, which received 510(k) clearance for migraine care. The program aims to provide drug-free pain relief, AI-powered trigger tracking, and proactive prevention. Client response has been strong, with over 125 clients adopting the program, covering more than 2 million eligible lives, demonstrating the platform's broader applicability and the company's distribution strength.
Commercial Momentum and Pipeline Development
Hinge Health reported substantial pipeline growth in Q1 2026 compared to the prior year, particularly in the SMB segment, which saw over 100% YoY pipeline increase. The company continues to experience strong win rates and competitive takeaways. The Hinge Select offering also gained momentum, ending Q1 with 4,100 provider locations and expanded access through a national PBM partner and three of the five largest national health plans. These factors are expected to position the company well for the sales season in the second half of the year.
AI and Operational Efficiency Driving Leverage
Investments in AI and automation are driving significant operating leverage, with gross margin improving to 85% (up 400 bps YoY) and operating expenses decreasing to 60% of revenue (down from 69% YoY). Free cash flow reached $42 million, a 10x increase YoY, with a 23% margin. Management noted that slower hiring, partly due to AI-driven efficiency, contributed to the margin expansion. The company plans to continue reinvesting in product experience and innovation, even if it means maintaining gross margins rather than solely maximizing them.
Engagement Model and Member Yield Expansion
The company's engagement-based pricing model now covers approximately 80% of contracted lives, with almost all new customers adopting it. This model aligns incentives, demonstrating confidence in member engagement and clinical outcomes. Member yield is trending slightly north of 4%, driven by faster adoption in new clients and improved engagement in legacy clients, supported by AI-powered personalization and targeted enrollment initiatives. The long-term target for physical therapy yield is 9% to 12-15%, with migraine care further expanding this opportunity.
Stance on CMS ACCESS Model
Hinge Health decided not to apply to the CMS ACCESS program, despite applauding CMS's goal of expanding access to evidence-based care. The company expressed concerns that the program, as currently designed, would not deliver on the 'triple aim' (outcomes, experience, cost) and could put vulnerable Medicare populations at risk due to the removal of clinical oversight. Management hopes CMS will iterate on the model to better support high-quality care for Medicare beneficiaries.